FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, namely to monoclonal antibody or its antigen-binding fragment, which specifically binds protein gB of cytomegalovirus (CMV). Invention also discloses nucleic acid coding above antibody, host cell producing above antibody, pharmaceutical composition for treating CMV or induction of resistance to CMV containing said antibody. Invention discloses method of producing above antibody and its antigen-binding fragment, their use for treating CMV or increasing resistance to CMV.
EFFECT: invention is capable of specific binding with CMV, which provides effective treatment of diseases associated with CMV protein expression.
11 cl, 4 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES USED PASSIVE VACCINATION AGAINST INFLUENZA | 2012 |
|
RU2668802C2 |
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA | 2011 |
|
RU2635999C2 |
| ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
| ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) | 2017 |
|
RU2756275C2 |
| MONOCLONAL ANTIBODY ABLE TO BIND TO SPECIFIC DISCONTINUOUS EPITOPE PLACED IN AD1 REGION OF HUMAN CYTOMEGALOVIRUS GB GLYCOPROTEIN, AND ITS ANTIGEN-BINDING FRAGMENT | 2010 |
|
RU2542472C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTI-G PROTEIN ANTIBODIES | 2008 |
|
RU2526517C2 |
| STRUCTURES AIMED AT AFP/MHC PEPTIDE COMPLEXES AND TYPES OF THEIR USE | 2016 |
|
RU2754041C2 |
| ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2736720C2 |
| ANTIBODIES CAPABLE OF BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2016 |
|
RU2727018C1 |
